z-logo
open-access-imgOpen Access
<p>Autologous Cytokine-Induced Killer Cell Immunotherapy for Patients with High-Risk Diffuse Large B Cell Lymphoma After the First Complete Remission</p>
Author(s) -
Min Zhou,
Jing Wang,
Cuiping Li,
Jingyan Xu,
Bing Chen
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s254291
Subject(s) - medicine , cytokine induced killer cell , peripheral blood mononuclear cell , immunotherapy , cd8 , lymphoma , cd3 , diffuse large b cell lymphoma , gastroenterology , immunology , lymphocyte , oncology , immune system , biology , biochemistry , in vitro
To evaluate whether autologous cytokine-induced killer (CIK) cell immunotherapy improves the prognosis of patients with high-risk diffuse large B cell lymphoma (DLBCL) after the first complete remission (CR).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here